- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03316729
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
December 20, 2018 updated by: Daiichi Sankyo, Inc.
Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care.
Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Had protocol-defined pulmonary embolism (PE)
- Has stable systolic blood pressure (SBP) >90 mm Hg
- Has evidence of right ventricular (RV) dysfunction
- Has executed informed consent
Exclusion Criteria:
- Has history or plans for thrombotic therapy outside protocol allowance
- Has other contraindications for participation
- Has laboratory results outside protocol-specified limits
- Is pregnant, nursing, and/or not willing or able to use protocol-defined contraceptives
Has history or condition, or participated in another investigational study that (per protocol or in the opinion of the investigator) might compromise:
- the safety or well-being of the participant or the participant's offspring
- the safety of study staff
- the analysis of results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DS-9231
In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
|
DS-9231 in saline solution for intravenous infusion
Other Names:
|
PLACEBO_COMPARATOR: Placebo
In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
|
Placebo is matching saline solution for intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change from baseline in total thrombus volume
Time Frame: Baseline, 48-96 hours after study drug administration
|
Baseline, 48-96 hours after study drug administration
|
Percentage of participants with various gradations of decrease in total thrombus volume
Time Frame: Baseline, 48-96 hours after study drug administration
|
Baseline, 48-96 hours after study drug administration
|
Number of participants with major or clinically relevant nonmajor bleeding
Time Frame: within 7 days after study drug administration
|
within 7 days after study drug administration
|
Number of participants with adverse events
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change from baseline in total thrombus volume
Time Frame: Baseline, 30 days after study drug administration
|
Baseline, 30 days after study drug administration
|
Percentage of participants with with various gradations of decrease in total thrombus volume
Time Frame: 30 days after study drug administration
|
30 days after study drug administration
|
Percent change from baseline in RV/ left ventricle (LV) diameter ratio
Time Frame: Baseline, 48-96 hours and 30 days after study drug administration
|
Baseline, 48-96 hours and 30 days after study drug administration
|
Number of participants with PE-related deaths
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Number of participants who died from any cause
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Percentage of participants with clinical deterioration requiring additional rescue therapy for PE
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Number of participants with with recurrent, objectively documented venous thromboembolism (VTE)
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Participant-reported quality of life on a proprietary scale
Time Frame: Baseline, Day 30 after study drug administration
|
Baseline, Day 30 after study drug administration
|
Number of participants with major or clinically relevant nonmajor bleeding
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Number of participants re-hospitalized for any reason
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Number of participants with non-bleeding adverse events (AEs)
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Number of participants with anti-drug antibodies (ADAs)
Time Frame: within 30 days after study drug administration
|
within 30 days after study drug administration
|
Plasma concentration of DS-9231
Time Frame: Baseline to 30 days after study drug administration
|
Baseline to 30 days after study drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
January 1, 2018
Primary Completion (ANTICIPATED)
February 1, 2020
Study Completion (ANTICIPATED)
February 1, 2020
Study Registration Dates
First Submitted
October 17, 2017
First Submitted That Met QC Criteria
October 19, 2017
First Posted (ACTUAL)
October 20, 2017
Study Record Updates
Last Update Posted (ACTUAL)
December 24, 2018
Last Update Submitted That Met QC Criteria
December 20, 2018
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS9231-A-U201
- 2017-000552-25 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
GlaxoSmithKlineCompleted
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
-
Suzhou Zenith Vascular Scitech Co., Ltd.Not yet recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismChina
Clinical Trials on DS-9231
-
Ludwig Institute for Cancer ResearchDaiichi Sankyo Co., Ltd.; Austin HealthCompletedMalignant Solid Tumor | Metastatic EphA2 Positive CancerAustralia
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Daiichi Sankyo Co., Ltd.CompletedAdvanced Solid Malignant TumorsJapan
-
Institut National de la Santé Et de la Recherche...Ultragenyx Pharmaceutical IncCompletedGlut1 Deficiency SyndromeFrance
-
Daiichi Sankyo, Inc.CompletedHepatic ImpairmentUnited States
-
Daiichi Sankyo Co., Ltd.Completed
-
Daiichi Sankyo Co., Ltd.Completed
-
Daiichi Sankyo Co., Ltd.Terminated
-
Daiichi Sankyo Co., Ltd.Recruiting
-
Hospital St. Joseph, Marseille, FranceRecruitingPancreatitis, ChronicFrance